2. UroToday Home
  3. Conference Highlights
  4. IBCN 2020

IBCN 2020: Age is Associated with Response to Immune Checkpoint Blockade in Advanced Urothelial Carcinoma

(UroToday.com) Dr. Wolfgang Beck, University of North Carolina, Chapel Hill, North Carolina, USA presented “Age is associated with response to immune checkpoint blockade in advanced urothelial carcinoma.”  The investigators performed post hoc analysis on IMvigor210 data and identified an age cutoff point of 72 years, with older patients achieving a relatively better response than younger patients.  Dr. Beck et al. then included age among other validated clinical and genomic predictors to create a model for immune checkpoint blockade response in advanced disease.  These data have implications on the selection of first-line therapy in de novo advanced disease in elderly patient populations.

IBCN_2020_Beck_1.png


Presented by: Wolfgang Beck, MD-PhD Student, University of North Carolina, Chapel Hill, North Carolina, USA

Written by: Dr. Patrick Hensley, Urologic Oncology Fellow at MD Anderson Cancer Center, Twitter: @pjhensley11, with Ashish Kamat, MD, MBBS, President of The International Bladder Cancer Network (IBCN), The International Bladder Cancer Group (IBCG), and Professor of the Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, Twitter: @UroDocAsh, at the International Bladder Cancer Network (IBCN) Annual Meeting, #IBCN2020, October 17, 2020.